Page last updated: 2024-11-02

pioglitazone and Purpura, Thrombocytopenic, Idiopathic

pioglitazone has been researched along with Purpura, Thrombocytopenic, Idiopathic in 1 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Purpura, Thrombocytopenic, Idiopathic: Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kasono, K1
Nishida, J1
Tamemoto, H1
Fudaka, K1
Namai, K1
Kajio, H1
Masatoshi, K1
Kanazawa, Y1
Kawakami, M1

Other Studies

1 other study available for pioglitazone and Purpura, Thrombocytopenic, Idiopathic

ArticleYear
Thiazolidinediones increase the number of platelets in immune thrombocytopenic purpura mice via inhibition of phagocytic activity of the reticulo-endothelial system.
    Life sciences, 2002, Sep-13, Volume: 71, Issue:17

    Topics: Animals; Antibody-Dependent Cell Cytotoxicity; Autoantibodies; Blood Platelets; COS Cells; Disease M

2002